CN1310640C - 药物组合物 - Google Patents

药物组合物 Download PDF

Info

Publication number
CN1310640C
CN1310640C CNB028198611A CN02819861A CN1310640C CN 1310640 C CN1310640 C CN 1310640C CN B028198611 A CNB028198611 A CN B028198611A CN 02819861 A CN02819861 A CN 02819861A CN 1310640 C CN1310640 C CN 1310640C
Authority
CN
China
Prior art keywords
mycophenolic acid
tablet
enteric coating
dosage forms
solid dosage
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CNB028198611A
Other languages
English (en)
Chinese (zh)
Other versions
CN1564684A (zh
Inventor
J·德德里希斯
T·里伽西
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9924043&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN1310640(C) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis AG filed Critical Novartis AG
Publication of CN1564684A publication Critical patent/CN1564684A/zh
Application granted granted Critical
Publication of CN1310640C publication Critical patent/CN1310640C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Furan Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CNB028198611A 2001-10-17 2002-10-16 药物组合物 Expired - Fee Related CN1310640C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0124953.1 2001-10-17
GBGB0124953.1A GB0124953D0 (en) 2001-10-17 2001-10-17 Organic Compounds

Publications (2)

Publication Number Publication Date
CN1564684A CN1564684A (zh) 2005-01-12
CN1310640C true CN1310640C (zh) 2007-04-18

Family

ID=9924043

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB028198611A Expired - Fee Related CN1310640C (zh) 2001-10-17 2002-10-16 药物组合物

Country Status (31)

Country Link
US (3) US20050013859A1 (enExample)
EP (1) EP1438040B2 (enExample)
JP (2) JP2005508959A (enExample)
KR (1) KR100671367B1 (enExample)
CN (1) CN1310640C (enExample)
AR (2) AR036813A1 (enExample)
AT (1) ATE374023T1 (enExample)
AU (1) AU2002338897B2 (enExample)
BR (1) BR0213355A (enExample)
CA (1) CA2460574A1 (enExample)
CO (1) CO5390076A1 (enExample)
CY (1) CY1107841T1 (enExample)
DE (1) DE60222687T3 (enExample)
DK (1) DK1438040T4 (enExample)
EC (2) ECSP024342A (enExample)
ES (1) ES2292819T5 (enExample)
GB (1) GB0124953D0 (enExample)
HU (1) HU231114B1 (enExample)
IL (2) IL160968A0 (enExample)
MX (1) MXPA04003636A (enExample)
MY (1) MY139206A (enExample)
NO (1) NO341804B1 (enExample)
NZ (1) NZ532280A (enExample)
PE (1) PE20030476A1 (enExample)
PL (2) PL234541B1 (enExample)
PT (1) PT1438040E (enExample)
RU (2) RU2338528C2 (enExample)
SI (1) SI1438040T2 (enExample)
TW (1) TWI333861B (enExample)
WO (1) WO2003032978A1 (enExample)
ZA (1) ZA200401977B (enExample)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0124953D0 (en) 2001-10-17 2001-12-05 Novartis Ag Organic Compounds
AR045957A1 (es) * 2003-10-03 2005-11-16 Novartis Ag Composicion farmaceutica y combinacion
CN101052631A (zh) * 2004-07-20 2007-10-10 特瓦药厂私人有限公司 结晶霉酚酸钠
GB0419355D0 (en) * 2004-08-31 2004-09-29 Novartis Ag Organic compounds
WO2006086498A2 (en) * 2005-02-08 2006-08-17 Aspreva Pharmaceuticals Sa Treatment of vascular, autoimmune and inflammatory diseases using low dosages of impdh inhibitors
WO2006086500A2 (en) * 2005-02-08 2006-08-17 Aspreva Pharmaceuticals Sa Compositions and methods for treating vascular, autoimmune and inflammatory diseases
EP1940388A2 (en) * 2005-09-30 2008-07-09 Novartis AG Dpp iv inhibtor for use in the treatment of autoimmune diseases and graft rejection
EP1965760B1 (de) 2005-12-21 2013-02-27 Basf Se Feinteiliges quervernetztes polyvinylpyrrolidon als tablettensprengmittel
CA2640283A1 (en) * 2006-02-13 2007-08-23 Novartis Ag High dosage of mycophenolic acid (mpa)
WO2008148742A2 (de) 2007-06-06 2008-12-11 Basf Se Pharmazeutische formulierung für die herstellung von schnell zerfallenden tabletten
US8568780B2 (en) 2007-06-06 2013-10-29 Basf Se Pharmaceutical formulation for the production of rapidly disintegrating tablets
MX2010001711A (es) * 2007-08-13 2010-03-11 Panacea Biotec Ltd Composiciones de liberacion extendida que comprenden micofenolato sodico y procedimientos de las mismas.
AU2009220779A1 (en) * 2008-03-05 2009-09-11 Panacea Biotec Limited Modified release pharmaceutical compositions comprising mycophenolate and processes thereof
US20100010082A1 (en) * 2008-07-09 2010-01-14 Aspreva International Ltd. Formulations for treating eye disorders
US20110086102A1 (en) * 2009-10-13 2011-04-14 Teva Pharmaceutical Industries Ltd. Delayed release compositions
WO2011046546A1 (en) * 2009-10-13 2011-04-21 Teva Pharmaceutical Industries Ltd. Delayed release compositions
WO2011051967A2 (en) * 2009-10-23 2011-05-05 Alkem Laboratories Ltd Pharmaceutical compositions comprising mycophenolate and processes for preparing thereof
GB201100786D0 (en) 2011-01-18 2011-03-02 Ems Sa Pharmaceutical compositions of immunosuppressants
CN102793658A (zh) * 2012-08-23 2012-11-28 无锡福祈制药有限公司 一种含有麦考酚酸或麦考酚酸盐的骨架型制剂及其包衣片
CN103845323B (zh) * 2012-11-30 2018-02-02 重庆华邦制药有限公司 麦考酚酸及其盐肠溶制剂和制备方法
WO2014167442A1 (en) 2013-03-26 2014-10-16 Wockhardt Limited Pharmaceutical compositions comprising mycophenolic acid or salts thereof
CN106727403A (zh) * 2017-01-03 2017-05-31 无锡福祈制药有限公司 一种麦考酚钠肠溶片及其制备方法
JP7385474B2 (ja) * 2017-03-13 2023-11-22 オカヴァ ファーマシューティカルズ， インコーポレイテッド 非ヒト哺乳動物にミコフェノール酸活性剤を送達すための方法および組成物
CA3102412A1 (en) 2018-06-06 2019-12-12 Metavant Sciences Gmbh Methods of treating subjects having diabetes with chronic kidney disease
WO2019238647A1 (en) * 2018-06-14 2019-12-19 Poxel Film-coated tablet comprising a triazine derivative for use in the treatment of diabetes
RU2723255C2 (ru) * 2018-11-14 2020-06-09 Общество с ограниченной ответственностью "Изварино Фарма" Экструдат с микофенолятом натрия для получения пероральной твердой лекарственной формы
EP4438037A1 (en) * 2021-01-28 2024-10-02 Priothera SAS Methods of treatment with s1p receptor modulators
EP4346790A4 (en) * 2021-05-26 2025-04-16 The Texas A&M University System Biodegradable mucoadhesive pharmaceutical formulations and methods thereof
CN117442580B (zh) * 2023-12-21 2024-04-05 泊诺(天津)创新医药研究有限公司 一种高生物利用度麦考酚钠肠溶片及其制备方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1215991A (zh) * 1996-04-12 1999-05-05 诺瓦提斯公司 霉酚酸盐的包有肠溶衣的药物组合物

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1157100A (en) † 1966-09-27 1969-07-02 Ici Ltd Pharmaceutical Compositions
GB1157099A (en) * 1966-09-27 1969-07-02 Ici Ltd Fermentation Process
GB1203328A (en) * 1968-06-04 1970-08-26 Ici Ltd Pharmaceutical compositions
US3705946A (en) * 1971-05-25 1972-12-12 Lilly Co Eli Method of treating hyperuricemia
US3880995A (en) * 1973-05-14 1975-04-29 Lilly Co Eli Treatment of arthritis with mycophenolic acid and derivatives
JPS56127093A (en) * 1980-03-10 1981-10-05 Ajinomoto Co Inc Preparation of mycophenolic acid
US4959387A (en) * 1986-01-23 1990-09-25 Syntex (U.S.A.) Inc. Mycophenolic acid derivatives in the treatment of rheumatoid arthritis
US4725622A (en) * 1986-01-23 1988-02-16 Syntex (U.S.A.) Inc. Mycophenolic acid derivatives in the treatment of rheumatoid arthritis
US4753935A (en) * 1987-01-30 1988-06-28 Syntex (U.S.A.) Inc. Morpholinoethylesters of mycophenolic acid and pharmaceutical compositions
US4748173A (en) * 1987-01-30 1988-05-31 Syntex (U.S.A.) Inc. Heterocyclic aminoalkyl esters of mycophenolic acid and derivatives thereof and pharmaceutical compositions
US5177072A (en) * 1987-01-30 1993-01-05 Syntex (U.S.A.) Inc. Treatment of autoimmune inflammatory, and psoriatic diseases with heterocyclic aminoalkyl esters of mycophenolic acid and derivatives
AU3178293A (en) * 1992-11-24 1994-06-22 Syntex (U.S.A.) Inc. Use of mycophenolic acid, mycophenolate mofetil or derivate thereof to inhibit stenosis
WO1994012184A1 (en) * 1992-11-24 1994-06-09 Syntex (U.S.A.) Inc. Use of mycophenolic acid, mycophenolate mofetil or derivate thereof to inhibit stenosis
US5843479A (en) * 1993-02-26 1998-12-01 The Procter & Gamble Company Bisacodyl dosage form with multiple enteric polymer coatings for colonic delivery
US5656290A (en) * 1993-02-26 1997-08-12 The Procter & Gamble Company Bisacodyl dosage form with multiple enteric polymer coatings for colonic delivery
DK0686034T3 (da) * 1993-02-26 2001-08-27 Procter & Gamble Bisacodyl-doseringsform
US5651983A (en) * 1993-02-26 1997-07-29 The Procter & Gamble Company Bisacodyl dosage form for colonic delivery
US5455045A (en) * 1993-05-13 1995-10-03 Syntex (U.S.A.) Inc. High dose formulations
ES2248793T3 (es) * 1993-10-01 2006-03-16 Roche Palo Alto Llc Suspensiones orales de alta dosis de mofetil micofenolato.
WO1995011024A1 (en) * 1993-10-19 1995-04-27 The Procter & Gamble Company Picosulphate dosage form
US5514663A (en) * 1993-10-19 1996-05-07 The Procter & Gamble Company Senna dosage form
US5482718A (en) * 1994-03-23 1996-01-09 Hoffmann-La Roche Inc. Colon-targeted delivery system
US5686106A (en) * 1995-05-17 1997-11-11 The Procter & Gamble Company Pharmaceutical dosage form for colonic delivery
WO2000067773A2 (en) * 1999-05-10 2000-11-16 Novartis Ag Combinations of immunosupressive agents for the treatment or prevention of graft rejections
HUP9903226A2 (en) * 1999-09-23 2002-08-28 Gyogyszerki Process for producing mycophenolic acid and derivatives thereof
EP1259631B1 (en) * 2000-02-29 2005-10-12 Biocon Limited Manufacture and purification of mycophenolic acid
GB0124953D0 (en) 2001-10-17 2001-12-05 Novartis Ag Organic Compounds
GB0301259D0 (en) 2003-01-20 2003-02-19 Novartis Ag Organic compounds

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1215991A (zh) * 1996-04-12 1999-05-05 诺瓦提斯公司 霉酚酸盐的包有肠溶衣的药物组合物

Also Published As

Publication number Publication date
US20050013859A1 (en) 2005-01-20
DE60222687T3 (de) 2020-03-05
TWI333861B (en) 2010-12-01
US20120237601A1 (en) 2012-09-20
ECSP024341A (es) 2003-12-01
ZA200401977B (en) 2006-05-31
MXPA04003636A (es) 2004-07-27
ATE374023T1 (de) 2007-10-15
BR0213355A (pt) 2006-05-23
KR20050037409A (ko) 2005-04-21
NO341804B1 (no) 2018-01-22
CN1564684A (zh) 2005-01-12
IL160968A0 (en) 2004-08-31
AU2002338897B2 (en) 2006-10-19
SI1438040T2 (sl) 2020-02-28
GB0124953D0 (en) 2001-12-05
EP1438040B1 (en) 2007-09-26
PT1438040E (pt) 2008-01-02
MY139206A (en) 2009-08-28
PL415001A1 (pl) 2016-02-29
RU2007130786A (ru) 2009-02-20
PL367738A1 (en) 2005-03-07
DK1438040T4 (da) 2020-01-27
PL234541B1 (pl) 2020-03-31
SI1438040T1 (sl) 2008-04-30
JP2009137996A (ja) 2009-06-25
EP1438040B2 (en) 2019-10-16
NO20041785L (no) 2004-05-03
DE60222687T2 (de) 2008-07-17
US20100210717A1 (en) 2010-08-19
ES2292819T3 (es) 2008-03-16
CY1107841T1 (el) 2013-06-19
HU231114B1 (hu) 2020-09-28
EP1438040A1 (en) 2004-07-21
CO5390076A1 (es) 2004-04-30
JP2005508959A (ja) 2005-04-07
HUP0600451A2 (en) 2006-09-28
IL160968A (en) 2016-04-21
DE60222687D1 (de) 2007-11-08
DK1438040T3 (da) 2008-02-04
PE20030476A1 (es) 2003-07-30
RU2381026C2 (ru) 2010-02-10
AR085778A2 (es) 2013-10-30
HK1067861A1 (en) 2005-04-22
ES2292819T5 (es) 2020-05-29
CA2460574A1 (en) 2003-04-24
NZ532280A (en) 2007-05-31
AR036813A1 (es) 2004-10-06
RU2338528C2 (ru) 2008-11-20
WO2003032978A1 (en) 2003-04-24
ECSP024342A (es) 2003-03-10
RU2004115332A (ru) 2005-04-20
KR100671367B1 (ko) 2007-01-19

Similar Documents

Publication Publication Date Title
CN1310640C (zh) 药物组合物
CN1104238C (zh) 霉酚酸盐的包有肠溶衣的药物组合物
CN1195511C (zh) 富马酸衍生物在移植药物中的应用
TWI354569B (en) Coated tablet formulation and method
CN1589139A (zh) 调节释放坦洛新片剂
AU2002338897A1 (en) Pharmaceutical compositions comprising mycophenolic acid or mycophenolate salt
CN101652139A (zh) 药物组合物
CN1314396C (zh) 左旋奥硝唑在制备抗厌氧菌感染药物的应用
CN1081029C (zh) 丙戊酸金属盐缓释片剂
CN1226162A (zh) 包膜马来酸三甲丁酯片剂
JPH09511760A (ja) シサプリドの経口用徐放性組成物
CN1762357A (zh) 一种莫西沙星口服药物制剂及其制备方法
CN1500491A (zh) 口服罗红霉素控释制剂
CN101043876A (zh) 包含可压性差的活性剂和生育酚聚乙二醇琥珀酸酯(tpgs)的片剂
CN1863509A (zh) 包含麦考酚酸或麦考酚酸钠的多粒子药物组合物和与雷帕霉素的组合
CN1568180A (zh) 控制释放4－氨基－6,7－二甲氧基－2－(5－甲磺酰氨基－1,2,3,4－四氢异喹啉－2－基)－5－(2－吡啶基)喹唑啉的药物制剂
HK1067861B (en) Pharmaceutical compositions comprising mycophenolic acid or mycophenolate salt
CN1976683A (zh) 具有胃滞留性质的替地沙米口服持续释放制剂
HK1068795A (en) Pharmaceutical formulations for the controlled release of 4-amino-6,7-dimethoxy-2-(5-methanesulfonamido-1,2,3,4-tetrahydroisoq uinol-2-yl)-5-(2-pyridyl) quinazo-line
HK1020888B (en) Coated trimebutine maleate tablet

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C56 Change in the name or address of the patentee

Owner name: NOVARTIS CO., LTD.

Free format text: FORMER NAME: NOVARTIS AG

CP01 Change in the name or title of a patent holder

Address after: Basel, Switzerland

Patentee after: NOVARTIS AG

Address before: Basel, Switzerland

Patentee before: Novartis AG

CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20070418

Termination date: 20211016

CF01 Termination of patent right due to non-payment of annual fee